Hershberg: Restricting US-China biotech transactions via BIOSECURE Act is net negative
Elliot Hershberg · The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation · Nov 14, 2025 · at 21:07
Elliot Hershberg, venture partner at Amplify, addresses US regulatory policy and geopolitical restrictions surrounding American and Chinese biotechnology transactions.
0:00 / 0:15exact quote · 15.6s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I do think that there's some nuance in terms of how we think about regulation for this, right? It's probably not biosecure where you are totally trying to restrict Relationships and transactions between the U S and China, because that's just sort of net negative.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Elliot Hershberg
Hershberg: Zero Amplify portfolio companies are running first-in-human trials in US
“So we have three companies in the next 12 to 18 months that will be starting first in human trials. You know, guess how many are actually doing their first studies in the United States?”
Hershberg: Clinical trial costs per patient ballooned from $10,000 to $500,000
“So when George Yonkopoulos started Regeneron, it cost about 10,000 dollars per patient in trial. That's ballooned to 500,000 dollars.”
Hershberg: Clinical research market consolidated into 12 primary providers
“So it actually turns out that there's been this enormous consolidation of the clinical research organization market that's come down to about a dozen providers who have each done roughly 40 acquisitions across 30 years.”
Hershberg: Biotech startups generate two-thirds of newly approved drugs
“Biotech startups now make two thirds of the drugs that go to market.”
Hershberg: AI biology platforms where the platform is the product remain compelling
“This is where I'm sort of an unequivocal platform bull still is that I think like one of the most exciting opportunities for AI and biology is this sort of world that we're going to where the platform is the product, right?”